| 标题： | 中国女性乳腺癌患者甲状腺炎及甲状腺功能异常管理专家共识（2024版） |
| title： | Chinese expert consensus recommendations for management of thyroiditis and thyroid dysfunction in female patients with early breast cancer (2024 edition) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 中国乳腺疾病专业临床医生 |
| Guide users： | Clinicians specializing in breast diseases in China |
| 证据分级方法： | GRADE分级系统并结合国内临床研究和专家临床经验 |
| Evidence grading method： | The evidence grading system was developed by incorporating elements of the GRADE system along with insights gleaned from clinical studies conducted in China and expert clinical experience. |
| 制定单位： | 中国抗癌协会乳腺肿瘤整合康复专业委员会、中国抗癌协会肿瘤临床研究管理学专业委员会、中国医师协会外科医师分会乳腺外科专家工作组、国家肿瘤质控中心乳腺癌专家委员会、重庆市临床医学研究联合会、重庆市中西医结合学会甲状腺疾病专业委员会、重庆抗癌协会肿瘤内分泌专业委员会 |
| Formulating unit： | Breast Cancer Rehabilitation Committee of China Anti-Cancer Association, The Society of Clinical Cancer Research Administration of China Anti-Cancer Association, Breast surgery expert working group of Surgeons Branch of Chinese Medical Doctor Association, the Breast Cancer Expert Committee of the National Cancer Quality Control Center, Chongqing Federation of Clinical Medical Research, The Society of Thyroid Disease of Chongqing Association of the Integration of Traditional and Western Medicine, The Society of Onco-endocrinology of Chongqing Anti-Cancer Association |
| 注册时间： | 2024-09-03 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN390 |
| Registration number： | |
| 指南制订的目的： | 乳腺癌患者合并甲状腺炎及甲状腺功能异常广泛存在，影响患者的综合治疗及生命健康。近年来，乳腺癌伴随的甲状腺疾病逐渐受到关注，目前缺乏针对乳腺癌患者伴发甲状腺炎及甲状腺功能异常的诊疗指南或共识。因此，中国抗癌协会乳腺肿瘤整合康复专业委员会、中国抗癌协会肿瘤临床研究管理学专业委员会、中国医师协会外科医师分会乳腺外科专家工作组、国家肿瘤质控中心乳腺癌专家委员会、重庆市临床医学研究联合会，重庆市中西医结合学会甲状腺疾病专业委员会，重庆抗癌协会肿瘤内分泌专业委员会组织相关专家，结合最新相关文献、国内外指南、共识及多个诊疗中心的临床经验，深入探讨并编写了《中国女性乳腺癌患者甲状腺炎及甲状腺功能异常管理专家共识（2024版）》，希望通过本共识规范乳腺癌患者伴随的甲状腺炎及甲状腺功能异常的诊疗，改善患者预后。 |
| Purpose of the guideline： | The coexistence of thyroiditis and thyroid dysfunction in breast cancer patients is widely observed, impacting the treatment and prognosis of breast cancer patients. In long-term survival cases of breast cancer, there is a notable high incidence of accompanying thyroiditis and thyroid dysfunction, a trend that has gained increasing attention in recent years. Currently, there is a lack of consensus or guidelines regarding the diagnosis and treatment of thyroiditis and thyroid dysfunction in breast cancer patients. Based on the recent related documents, domestic and foreign guidelines and clinical experience of multiple clinical centers, The Society of Clinical Cancer Research Administration of China Anti-Cancer Association, in collaboration with The Society of Clinical Cancer Research Administration of China Anti-Cancer Association, The Society of Breast Cancer Integration and Rehabilitation of China Anti-Cancer Association, Chongqing Federation of Clinical Medical Research, The Society of Thyroid Disease of Chongqing Association of the Integration of Traditional and Western Medicine and The Society of Onco-endocrinology of Chongqing Anti-Cancer Association, has organized relevant experts to extensively discuss and formulate the " Chinese expert consensus recommendations for management of thyroiditis and thyroid dysfunction in female patients with breast cancer (2024 edition)", aiming to standardize the diagnosis and treatment of thyroiditis and thyroid function disorders in breast cancer patients, and improve the patients’ prognosis. |
